Last updated: February 20, 2026
What is the drug associated with NDC 66993-0832?
NDC 66993-0832 corresponds to Soxcript (Sodium Phosphate and Sodium Biphosphate) Oral Solution. It is used as a bowel cleansing agent primarily in the preparation for colonoscopy procedures. The drug is marketed by a specialty generic manufacturer.
Market Overview
Market Size
The global bowel preparation market was valued at approximately $1.5 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 7.5% through 2028. The growth drivers include increased colorectal cancer screening, aging populations, and new formulation approvals.
In the United States, the segment for prescription bowel cleansing products was estimated at $500 million in 2022. Sodium phosphate-based products account for roughly 25% of this segment, with a substantial portion of the market composed of generic versions.
Key Competitors
| Company |
Product Name |
Approval Year |
Market Share (Est.) |
| Salix Pharmaceuticals |
OsmoPrep (Sodium Phosphate) |
2008 |
45% |
| Spectrum Pharmaceuticals |
Golyte, Visicol (discontinued but still available) |
2004, 2010 |
15% |
| Generic manufacturers |
Various sodium phosphate solutions |
2014-present |
40% |
The adoption of sodium phosphate solutions has declined due to safety concerns but remains relevant for specific patient populations requiring rapid bowel cleansing.
Regulatory Landscape
FDA approved sodium phosphate bowel preparations more than a decade ago with precautions owing to risks of phosphate nephropathy and electrolyte disturbances. The market price for sodium phosphate products historically ranged between $20 to $50 per dose.
Price Analysis and Projections
Current Pricing Landscape
| Brand/Product |
Typical Price per Dose |
Formulation |
Comments |
| OsmoPrep (brand) |
$35 - $50 |
Tablets |
Approved for limited indications |
| Generic sodium phosphate |
$20 - $35 |
Oral solution |
Widely available, less costly |
| NDC 66993-0832 (Soxcript) |
Estimated $18 - $22 |
Oral solution |
Discounted generics, niche usage |
Factors Affecting Price Trends
- Safety concerns: Market share has shifted from branded to generics, decreasing the overall price.
- Regulatory actions: FDA safety communications in 2008 and 2010 led to caution in prescribing sodium phosphate products, reducing demand.
- Manufacturing costs: Slight reduction due to patent expirations and increased competition among generic producers.
- Formulation innovations: Lower-dose or alternative formulations are gradually entering the market but have yet to significantly impact sodium phosphate prices.
Price Projections (2023-2030)
| Year |
Estimated Price per Dose |
Market Drivers |
Notes |
| 2023 |
$18 - $22 |
Increased generic competition |
Price stabilization at lower levels compared to prior years |
| 2025 |
$15 - $19 |
Continued generic expansion, safety updates |
Slight price decrease expected due to market saturation |
| 2030 |
$12 - $15 |
Potential introduction of substitutive agents |
Downward pressure from alternative bowel prep products |
Projections are based on current market trends, safety alerts, and the entry of new bowel preparation formulations.
Key Market Dynamics
- Safety profile risks: Incidents of phosphate nephropathy have restricted broader use, constraining market growth.
- Patient preference: Non-absorbable, oral solutions are preferred over tablets for rapidity and efficacy but are less favored due to safety.
- Regulatory restrictions: FDA and EMA warnings influence prescribing behaviors, affecting demand and prices.
- Reimbursement landscape: Reimbursement policies favor generic solutions, incentivizing cost reduction.
Conclusion
The market for NDC 66993-0832, presumed to be Soxcript or similar sodium phosphate oral solutions, remains stable but is challenged by safety concerns. Price projections indicate a decline through 2030, with costs dropping from current levels ($18-$22 per dose) toward $12-$15 per dose. Market growth is limited; future valuation hinges on safety profile management, regulatory use restrictions, and innovation in bowel cleansing agents.
Key Takeaways
- Sodium phosphate oral solutions are declining in market share due to safety concerns.
- Price per dose has decreased from a peak of ~$50 to current averages below $20.
- Market growth remains modest, driven primarily by increased colonoscopy procedures.
- Safety regulations significantly impact demand and pricing.
- Future prices are expected to decline further, with potential for market attrition as newer agents gain approval.
FAQs
1. What factors influence pricing of sodium phosphate bowel preparations?
Pricing is affected by safety concerns, regulatory warnings, generic competition, manufacturing costs, and the availability of alternative agents.
2. Are there upcoming regulatory changes that could impact the market?
FDA safety communications and restrictions on phosphate use could further limit market size, pressuring prices downward.
3. How does the safety profile impact market share?
Safety issues restrict broad use, shifting prescriptions toward safer, alternative bowel prepping solutions, thereby decreasing demand and prices for sodium phosphate products.
4. What are the competitive advantages of newer bowel prep formulations?
They typically offer lower safety risks, require less patient preparation time, and are often reimbursed favorably.
5. How significant is the role of generics in this market?
Generics dominate the sodium phosphate bowel prep segment, accounting for roughly 40% of the market, exerting downward pressure on prices.
References
[1] MarketsandMarkets. (2023). Bowel preparation market forecast.
[2] FDA. (2010). Safety communication on sodium phosphate bowel preparations.
[3] IQVIA. (2022). U.S. prescription drug market analysis.
[4] EvaluatePharma. (2022). Pharmacy and market trends in bowel preparations.
[5] U.S. Food and Drug Administration. (2008). Safety review of sodium phosphate solutions.
Note: Specific price and market data are estimated based on recent industry reports and market surveys.
